the aid library

LIST OPTIONS

Filter

2880

Water, sanitation, hygiene and health. A primer for health professionals

World Health Organization WHO (2019) C_WHO

This primer aims to guide health professionals on engaging with WASH-related issues. It gives an overview of WASH interventions and the status of WASH services globally and outlines key linkages with health. It provides examples of key actions that health actors can take to ensure WASH efforts effec... more

Download (490)

View PDF (669)

Antimicrobial Use and Resistance in Nigeria

Federal Ministries of Agriculture, Environment and Health (2017) C2

SITUATION ANALYSIS AND RECOMMENDATIONS

Download (279)

View PDF (312)

Rwanda: HEALTH SECTOR ANNUAL REPORT July 2015-June 2016

Ministry of Health, Rwanda (2016) C2

For the Fiscal Year 2015-2016, the Health Sector continued to implement actions meant to improve the availability, and access to quality healthcare. The following report highlights achievements registered by the health sector for the fiscal 2015-2016 in different health programs, as well as in the a... more

Download (177)

View PDF (239)

Handbook for Integrated Vector Management in the Americas

Pan American Health Organization PAHO ; World Health Organization WHO (2019) C_WHO

This document compiles the recommendations made by the World Health Organization (WHO) and the Pan American Health Organization (PAHO) to help professionals in charge of vector control programs in Latin America and the Caribbean at the national, subnational, and local level update their knowledge in... more

Documento operativo de aplicación del manejo integrado de vectores adaptado al contexto de las Américas

Pan American Health Organization PAHO ; World Health Organization WHO (2019) C_WHO

El presente documento reúne un conjunto de recomendaciones formuladas por la Organización Mundial de la Salud (OMS) y la Organización Panamericana de la Salud (OPS) para ayudar, a los profesionales encargados de los programas de control de vectores de Latinoamérica y el Caribe a nivel nacional, ... more

Download (312)

View PDF (252)

Manuel de gestion intégrée des vecteurs dans les Amériques

Pan American Health Organization PAHO ; World Health Organization WHO (2019) C_WHO

Le présent document rassemble une série de recommandations émises par l’Organisation mondiale de la Santé (OMS) et l’Organisation panaméricaine de la Santé (OPS) pour aider les professionnels chargés des programmes de lutte antivectorielle en Amérique latine et dans les Caraïbes aux niv... more

The increasing threat of vaccine-preventable diseases in Lebanon

World Health Organization WHO EMHJ – Vol. 30 No. 12 – 2024 (2024) C_WHO

Commentary

Guidelines for Addressing Disease Risks in Wildlife Trade

World Organisation for Animal Health WOAH (2024) CC

For thousands of years, humans have been using wildlife for commercial and subsistence purposes. Wildlife trade takes place at local, national and international levels, with different forms of wildlife, such as live animals, partly processed products and finished products. Wildlife is a vital source... more

From emergency response to long-term COVID-19 disease management - Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the r

World Health Organization WHO (2023) C_WHO

The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows: National action plan key activities, prioritized for the current context and the current ... more

Download (803)

View PDF (1155)

Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach

World Health Organization (2010) C_WHO

Download (443)

View PDF (321)

WHO laboratory manual for the diagnosis of diphtheria and other related infections
recommended

World Health Organization WHO (2022) C_WHO

Download (1793)

View PDF (4109)

Fason pou Gen Laviktwa sou Kolera
recommended

Ministry of Health, Haiti Centers for Disease Control and Prevention CDC (2011) C_CDC

The document titled "Fason pou Gen Laviktwa sou Kolera" (How to Achieve Victory over Cholera) provides comprehensive guidelines on the clinical presentation and management of cholera, particularly in the context of the 2010 Haiti outbreak. It emphasizes rapid rehydration as a lifesaving measure, det... more

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease... more

WHO Country Cooperation Strategy 2017 -2022 Malawi

World Health Organization WHO (2022) CC2

The Country Cooperation Strategy is the World Health Organization (WHO)’s reference for country work guiding planning and resource allocation through alignment with national health priorities and harmonization with other development partners. It clarifies roles and functions of WHO in supporting t... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Vaincre la méningite à l'horizon 2030 une feulle de route mondiale

Organisation Mondiale de la Santé OMS (2021) CC

La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du monde. La méningite bactérienne peut être à l’origine d’épidémies, entraîner la mort dans les... more